Last reviewed · How we verify
Calcium Channel Blockers, ACE-Inhibitor
This combination drug blocks calcium channels to reduce vascular smooth muscle contraction while inhibiting angiotensin-converting enzyme to reduce vasoconstriction and aldosterone secretion, together lowering blood pressure.
This combination drug blocks calcium channels to reduce vascular smooth muscle contraction while inhibiting angiotensin-converting enzyme to reduce vasoconstriction and aldosterone secretion, together lowering blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Calcium Channel Blockers, ACE-Inhibitor |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Combination antihypertensive (calcium channel blocker + ACE inhibitor) |
| Target | L-type calcium channels; Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Calcium channel blockers prevent calcium influx into vascular smooth muscle cells, causing vasodilation and reduced peripheral resistance. ACE inhibitors block the conversion of angiotensin I to angiotensin II, preventing a potent vasoconstrictor and reducing sodium and water retention. Together, these mechanisms provide complementary antihypertensive effects.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Headache
- Dizziness
- Peripheral edema
- Cough
- Fatigue
- Hyperkalemia
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- The GUARDIAN Pilot Trial (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Preventing Cognitive Decline by Reducing BP Target Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcium Channel Blockers, ACE-Inhibitor CI brief — competitive landscape report
- Calcium Channel Blockers, ACE-Inhibitor updates RSS · CI watch RSS
- University of Aarhus portfolio CI